IL6 and chronic kidney disease: In patients with moderate-severe CKD, TMAO represents an independent predictor of CV mortality [68,69], and its levels are directly proportional to inflammatory biomarkers (such as high-sensitivity C-reactive protein (hs-CRP) and IL-6).